Buprenorphine for treating cancer pain

Naing, Cho‐Min; Aung, Kyan; Yeoh, Peng Nam

doi:10.1002/14651858.cd009596

Cited by 3 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The other patient came in with an early symptom of no response to light. Research in India found that the frequency of leukocoria was as much as 98% (Sahu et al 1998), 87% in Ghana (Essuman et al 2010), 50% in Singapore (Aung et al 2009), and 65% in America (Butros et al 2002). Meanwhile, strabismus was found in 9 retinoblastoma patients (31%) in this study, as patients with metastasis to brain tissue were grouped into stage IV-B.…”

Section: Discussionsupporting

confidence: 43%

Longer Lag Time in Early-Stage Retinoblastoma

Citra

Utomo

Soebagjo

2022

FMI

View full text Add to dashboard Cite

Highlights: Patients with IRSS I stage have the longest lag time than IVB stage. Lag time is no significant with stage retinoblastoma. Abstract: Retinoblastoma is a rare neoplasm disease that occurs in children, generally under the age of two. Retinoblastoma is more prevalent in developing countries and is often associated with a late diagnosis. Such delays can lead to a poor prognosis. The time from the appearance of symptoms of retinoblastoma (onset) to the time of diagnosis is called lag time. Early diagnosis of retinoblastoma by paying attention to factors such as age, clinical symptoms, and laterality can help improve retinoblastoma survival rates, especially in developing countries. The purpose of this study was to analyze the relationship between the lag time to the stage of retinoblastoma patients at Dr. Soetomo General Academic Hospital, Surabaya, Indonesia. This study was a retrospective analytical observational study using secondary data from retinoblastoma patients at the Ophthalmology Outpatient Unit at Dr. Soetomo General Academic Hospital, Surabaya, from January 2014 to December 2018. The data were analyzed using Kendall's tau-C test. No significant correlation was found between lag time and stage (p = 0.339). Patients with International Retinoblastoma Staging System (IRSS) I stage had the longest lag time (on average 28 months), and patients with stage IVB had the shortest lag time (on average four months). There was no correlation between lag time and retinoblastoma stage. However, there was a trend of patients with early stages delaying hospital visits, while patients with advanced stages in earlier to the hospital.

show abstract

Section: Discussionsupporting

confidence: 43%

Longer Lag Time in Early-Stage Retinoblastoma

Citra

Utomo

Soebagjo

2022

FMI

View full text Add to dashboard Cite

show abstract

“…The present review has been reported according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) (Moher et al 2009 ) (Additional file 1 ). A protocol of this study is available (Naing et al 2012 ).…”

Section: Methodsmentioning

confidence: 99%

A meta-analysis of efficacy and tolerability of buprenorphine for the relief of cancer pain

2014

Self Cite

View full text Add to dashboard Cite

This study aimed to synthesize available evidence on the analgesic efficacy of buprenorphine in treating cancer pain and related adverse effects. We searched electronic databases for randomized controlled trials, assessing the efficacy of buprenorphine, regardless of delivery system. The primary endpoints were patient-reported ‘pain intensity’ and ‘pain relief’. Statistical heterogeneity among included studies was assessed with the I2 test. The summary relative risk (RR) and 95% CI were derived, if two or more studies reported the similar outcome. Sixteen RCTs (n = 1329) with buprenorphine were included: 8 transdermal (TD), 5 sublingual (SL), 2 intramuscular injection (IM) and 1 subcutaneous infusion (SC) studies; with both SL and IM routes being assessed in one study. Only a few studies reported the same outcome in a similar way, creating difficulty for pooling of the outcome data. Many studies had a high risk of bias. In 2 studies (n = 241), the ‘global impression change’ was significantly different between TD buprenorphine and the combined placebo and morphine (RR 1.35, 95% CI 1.14-1.59; I2: 42%); the ‘number-needed-to-treat’ (NNT) was 4.9 (95% CI: 3.1-10.9). In 2 studies (n = 331), ‘requirement for rescue SL buprenorphine’ was comparable between TD buprenorphine and placebo (RR 1.25, 95% CI 0.71-2.18; I2 : 40%). In 2 studies (n = 141), ‘incidence of nausea’ was less in TD buprenorphine (RR: 0.38, 95% CI: 0.2-0.71, I2: 0%, NNT: 9.3, 5.6-28.5). Due to the small number of participants in a small number of studies, the results of the present review provide insufficient evidence to position adequately the use of buprenorphine in treatment of cancer pain. Large multicenter RCTs that compare TD buprenorphine with standard analgesic treatment is needed to position TD buprenorphine in the therapeutic armamentarium of cancer pain treatment.Electronic supplementary materialThe online version of this article (doi:10.1186/2193-1801-3-87) contains supplementary material, which is available to authorized users.

show abstract